文献速递免疫规划

基于改良安卡拉痘苗病毒载体的多价呼吸道合胞病毒疫苗在3期临床研究中显示对老年人呼吸道合胞病毒所致疾病具有中等保护作用

A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
PubMed 文献 · Vaccine · 2024-10-25

本研究纳入≥60岁成人18348例,按1:1随机接种单剂MVA-BN-RSV疫苗或安慰剂,随访2022-2023季呼吸道合胞病毒(RSV)所致疾病。疫苗对≥3症状下呼吸道疾病(LRTD)效力42.9%(95%CI:-16.1;71.9),未达预设成功标准;对≥2症状LRTD效力59.0%(95%CI:34.7;74.3),对急性呼吸道疾病(ARD)效力48.8%(95%CI:25.8;64.7)。疫苗反应原性轻至中度,未发现安全性问题。

要点

  • ≥3症状LRTD疫苗效力42.9%,95%CI下限低于20%预设成功标准,主要目标未达成。
  • ≥2症状LRTD效力59.0%,ARD效力48.8%,95%CI下限均高于0。
  • 中和抗体平均 fold-increase 为1.7,RSV特异性IgG和IgA分别为2.9和4.3。

核心结论

  • MVA-BN-RSV诱导的针对RSV相关LRTD的保护作用欠佳,可能源于中和抗体应答欠佳。
  • 疫苗安全性可接受且免疫原性得到确认,总体显示MVA-BN载体构建体靶向其他疾病的前景。

研究设计与样本

  • 3期临床研究,≥60岁成人(伴或不伴基础慢性病)按1:1随机接受单剂MVA-BN-RSV疫苗或安慰剂。
  • 随访2022-2023季RSV感染所致疾病,最终疗效和安全性分析纳入18348例参与者。
  • 主要终点为≥3症状和≥2症状的RSV相关LRTD,ARD为关键次要终点。
  • 免疫应答于基线及接种后14天评估;安全性通过接种后7天征集性不良事件(AEs)、28天非征集性AEs及整个研究期严重不良事件(SAEs)评估。

主要发现

  • ≥3症状LRTD疫苗效力42.9%(95%CI:-16.1;71.9),95%CI下限低于20%预设成功标准,主要目标未达成。
  • ≥2症状LRTD疫苗效力59.0%(95%CI:34.7;74.3),ARD疫苗效力48.8%(95%CI:25.8;64.7)。
  • 疫苗诱导的免疫应答显示RSV A和B中和抗体平均fold-increase为1.7,RSV特异性IgG和IgA平均fold-increase分别为2.9和4.3。
  • 疫苗显示轻至中度反应原性,未发现安全性问题。

关键数值与推荐

  • ≥3症状LRTD疫苗效力42.9%(95%CI:-16.1;71.9),未达95%CI下限≥20%的预设成功标准。
  • ≥2症状LRTD疫苗效力59.0%(95%CI:34.7;74.3)。
  • ARD疫苗效力48.8%(95%CI:25.8;64.7)。
  • RSV A和B中和抗体平均fold-increase为1.7,RSV特异性IgG平均fold-increase为2.9,IgA为4.3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 主要目标未达成:≥3症状LRTD疫苗效力95%CI下限(-16.1)低于20%预设成功标准。
  • MVA-BN-RSV诱导的保护作用欠佳,可能源于中和抗体应答欠佳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on a nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV subtypes A and B, was assessed for efficacy against respiratory disease caused by RSV. Adults aged ≥60 years, with or without underlying chronic conditions, were enrolled and randomized in a 1:1 ratio to receive a single dose of vaccine or placebo and were followed for disease caused by RSV infection during the 2022-2023 season. The 2 primary endpoints were RSV-associated lower respiratory tract disease (LRTD) with ≥3 and ≥ 2 symptoms; acute respiratory disease (ARD) was a key secondary endpoint. The humoral RSV-specific immune response was assessed at baseline and 14 days post-vaccination. Safety was evaluated by collection of solicited adverse events (AEs) and unsolicited AEs for 7 and 28 days post-vaccination respectively, and SAEs for the entire study period. In total, 18,348 participants were included in the final efficacy and safety analyses. Vaccine efficacy was 42.9 % (95 % CI: -16.1; 71.9) against RSV-associated LRTD with ≥3 symptoms, 59.0 % (95 % CI: 34.7; 74.3) against LRTD with ≥2 symptoms, and 48.8 % (95 % CI: 25.8; 64.7) against ARD. The primary objective was not met for LRTD with ≥3 symptoms since the lower bound of the 95 % CI was below 20 %, the prespecified success criterion. The vaccine-elicited immune response showed mean fold-increases of 1.7 for RSV A and B neutralizing antibodies and 2.9 and 4.3 for RSV-specific IgG and IgA, respectively. The vaccine displayed mild to moderate reactogenicity, and no safety concerns were identified. MVA-BN-RSV induced suboptimal protection against RSV-associated LRTD, likely due to suboptimal neutralizing antibody response. The vaccine had an acceptable safety profile and confirmed immunogenicity, overall showing promise for MVA-BN-vectored constructs targeting other diseases. Trial Registration:Clinicaltrials.gov Identifier NCT05238025 (Registered February 14, 2022).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jordan E, Jenkins V, Silbernagl G, et al. A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study. Vaccine. 2024. PMID: 39461302. doi:10.1016/j.vaccine.2024.126427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。